BR0013281A - Derivados de arilmetil-carbonilamino-tiazol, processo para sua preparação e seu uso como agentes antitumorais - Google Patents
Derivados de arilmetil-carbonilamino-tiazol, processo para sua preparação e seu uso como agentes antitumoraisInfo
- Publication number
- BR0013281A BR0013281A BR0013281-0A BR0013281A BR0013281A BR 0013281 A BR0013281 A BR 0013281A BR 0013281 A BR0013281 A BR 0013281A BR 0013281 A BR0013281 A BR 0013281A
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- arylmethyl
- carbonylamino
- thiazole derivatives
- antitumor agents
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/372,832 US6114365A (en) | 1999-08-12 | 1999-08-12 | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
PCT/IB2000/001423 WO2001014353A1 (fr) | 1999-08-12 | 2000-08-11 | Derives d'arylmethyl-carbonylamino-thiazole utilisation de ceux-ci comme agents antitumoraux |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0013281A true BR0013281A (pt) | 2002-06-18 |
Family
ID=23469806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0013281-0A BR0013281A (pt) | 1999-08-12 | 2000-08-11 | Derivados de arilmetil-carbonilamino-tiazol, processo para sua preparação e seu uso como agentes antitumorais |
Country Status (36)
Country | Link |
---|---|
US (3) | US6114365A (fr) |
EP (1) | EP1204649B1 (fr) |
JP (1) | JP4864260B2 (fr) |
KR (2) | KR100773709B1 (fr) |
CN (1) | CN100410245C (fr) |
AP (1) | AP1853A (fr) |
AT (1) | ATE375987T1 (fr) |
AU (1) | AU782882B2 (fr) |
BG (1) | BG65484B1 (fr) |
BR (1) | BR0013281A (fr) |
CA (1) | CA2381097C (fr) |
CY (1) | CY1107108T1 (fr) |
CZ (1) | CZ303138B6 (fr) |
DE (1) | DE60036803T2 (fr) |
DK (1) | DK1204649T3 (fr) |
EA (1) | EA005375B1 (fr) |
EE (1) | EE04939B1 (fr) |
ES (1) | ES2295056T3 (fr) |
GE (1) | GEP20053475B (fr) |
HK (1) | HK1054233B (fr) |
HR (1) | HRP20020127B1 (fr) |
HU (1) | HUP0202492A3 (fr) |
IL (2) | IL147924A0 (fr) |
IS (1) | IS2594B (fr) |
MA (1) | MA25433A1 (fr) |
MX (1) | MXPA02001508A (fr) |
NO (1) | NO323576B1 (fr) |
NZ (1) | NZ517236A (fr) |
OA (1) | OA12047A (fr) |
PT (1) | PT1204649E (fr) |
RS (1) | RS50300B (fr) |
SI (1) | SI1204649T1 (fr) |
SK (1) | SK287373B6 (fr) |
UA (1) | UA72538C2 (fr) |
WO (1) | WO2001014353A1 (fr) |
ZA (1) | ZA200201117B (fr) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020150921A1 (en) * | 1996-02-09 | 2002-10-17 | Francis Barany | Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays |
US6407103B2 (en) | 1998-04-21 | 2002-06-18 | Bristol-Myers Squibb Pharma Company | Indeno [1,2-c] pyrazol-4-ones and their uses |
US6320050B1 (en) * | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
US6610846B1 (en) * | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
CN101481359A (zh) | 1999-04-15 | 2009-07-15 | 布里斯托尔-迈尔斯斯奎布公司 | 环状蛋白酪氨酸激酶抑制剂 |
US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US6114365A (en) | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
AU775373B2 (en) | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US20040048844A1 (en) * | 1999-10-20 | 2004-03-11 | Bristol-Myers Squibb Pharma Company | Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents |
US6291504B1 (en) | 1999-10-20 | 2001-09-18 | Dupont Pharmaceuticals Company | Acylsemicarbazides and their uses |
CA2430151A1 (fr) * | 2000-11-27 | 2002-06-20 | Pharmacia Italia S.P.A. | Derives phenylacetamido-pyrazole et leur utilisation comme agents antitumoraux |
WO2002044174A2 (fr) * | 2000-12-01 | 2002-06-06 | Bristol-Myers Squibb Pharma Company | Derives de 3-(2,4-dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-one et leur utilisation |
CA2430376A1 (fr) | 2000-12-08 | 2002-06-13 | David J. Carini | Semi-carbazides et leurs utilisations en tant qu'inhibiteurs de kinases dependantes des cyclines |
AU3113902A (en) * | 2000-12-21 | 2002-07-01 | Bristol Myers Squibb Co | Thiazolyl inhibitors of tec family tyrosine kinases |
DE60208630T2 (de) * | 2001-05-11 | 2006-08-17 | Pfizer Products Inc., Groton | Thiazolderivate und ihre Verwendung als cdk-Inhibitoren |
GEP20105095B (en) * | 2001-07-19 | 2010-10-25 | Pfizer Italia Srl | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
EP1724270A3 (fr) | 2001-07-19 | 2007-01-03 | Pfizer Italia S.r.l. | Dérivés de phenylacetamido-thiazole, leur procédé de préparation et leur utilisation en tant qu'agents antitumoraux |
EP1436286B1 (fr) * | 2001-09-27 | 2009-08-19 | Equispharm Co., Ltd. | Derives de fumagillol et procede permettant de les preparer |
EP1458382A1 (fr) * | 2001-12-21 | 2004-09-22 | Novo Nordisk A/S | Derives amide utiles en tant qu'activateurs de la glucokinase |
WO2004002481A1 (fr) * | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Activateurs de la glycokinase |
JP2006517577A (ja) * | 2003-02-12 | 2006-07-27 | ファイザー・インク | 抗増殖性の2−(スルホ−フェニル)−アミノチアゾール誘導体 |
MXPA05008878A (es) * | 2003-02-21 | 2005-10-05 | Pfizer | Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso. |
CA2520957C (fr) * | 2003-03-31 | 2013-08-06 | Sucampo Ag | Procede de traitement de maladie vasculaire hyperpermeable |
WO2005014591A1 (fr) * | 2003-07-15 | 2005-02-17 | L'oreal | 2-acylamino ou 2-sulfonylamino-1, 3-thiazoles en tant qu'agents de couplage pour la coloration d'oxydation de fibres keratiniques |
FR2857664B1 (fr) * | 2003-07-15 | 2007-12-14 | Oreal | Nouveaux derives thiazoles et utilisation de ces derives pour la teinture des fibres keratiniques |
US7351727B2 (en) * | 2003-09-02 | 2008-04-01 | Bristol-Myers Squibb Company | Inhibitors of 15-lipoxygenase |
US20050074424A1 (en) * | 2003-10-03 | 2005-04-07 | Lev Salnikov | Using polyion polymers with glucose infusion for a cancer selective chemotherapy compound and method |
US20070196395A1 (en) * | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
AU2005203930C1 (en) * | 2004-01-06 | 2012-02-23 | Vtv Therapeutics Llc | Heteroaryl-ureas and their use as glucokinase activators |
WO2006002119A2 (fr) | 2004-06-18 | 2006-01-05 | Gpc Biotech, Inc. | Utilisation d'inhibiteurs de kinase et leurs compositions |
EP1621539A1 (fr) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Dérivées d'urée cyclique substitués par un heterocycle, leur prépration et leur utilisation pharmaceutique comee inhibiteurs de kinases |
EP1621536A1 (fr) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Dérivés d'urées cycliques aminés, leur préparation et utilisation pharmaceutique en tant qu'inhibiteurs de Kinase |
EP2620150A3 (fr) * | 2004-08-13 | 2014-01-08 | Genentech, Inc. | Inhibiteurs à base de 2-amido thiazole d'enzymes utilisant l'ATP |
EP2096107A1 (fr) | 2004-12-23 | 2009-09-02 | GPC Biotech AG | Dérivés d'acide squarique dotés d'une activité anti-proliférante |
CA2618646A1 (fr) * | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine |
JP2009500378A (ja) * | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー/エス | グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素 |
EP1904467B1 (fr) | 2005-07-14 | 2013-05-01 | Novo Nordisk A/S | Activateurs de l'urée glucokinase |
EP1914234A1 (fr) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases |
US8138185B2 (en) * | 2007-01-09 | 2012-03-20 | Novo Nordisk A/S | Urea glucokinase activators |
AU2008204530B2 (en) * | 2007-01-11 | 2013-08-01 | Vtv Therapeutics Llc | Urea glucokinase activators |
WO2008098949A2 (fr) * | 2007-02-13 | 2008-08-21 | Ab Science | Procédé de synthèse de composés 2-aminothiazole comme inhibiteurs de kinase |
US8450348B2 (en) * | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
TWI437986B (zh) * | 2008-01-31 | 2014-05-21 | R Tech Ueno Ltd | 噻唑衍生物及使用該衍生物作為vap-1抑制劑之用途 |
US8232402B2 (en) | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
EP2112150B1 (fr) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Inhibiteurs Raf améliorés |
EP2112152A1 (fr) | 2008-04-22 | 2009-10-28 | GPC Biotech AG | Dihydropteridinones comme inhibiteurs Plk |
US8343996B2 (en) | 2008-11-13 | 2013-01-01 | Astrazeneca Ab | Azaquinolinone derivatives and uses thereof |
UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
TWI504598B (zh) * | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
EP2440556A1 (fr) * | 2009-06-10 | 2012-04-18 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de la phosphatidylinositol 3-kinase |
DE102009043260A1 (de) * | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate |
EP2325185A1 (fr) | 2009-10-28 | 2011-05-25 | GPC Biotech AG | Inhibiteur de Plk |
HU0900798D0 (en) | 2009-12-21 | 2010-03-01 | Vichem Chemie Kutato Kft | 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity |
US8883793B2 (en) | 2010-12-29 | 2014-11-11 | Development Center For Biotechnology | Tubulin inhibitors and methods of using the same |
RU2011122942A (ru) | 2011-06-08 | 2012-12-20 | Общество С Ограниченной Ответственностью "Асинэкс Медхим" | Новые ингибиторы киназ |
CN103387551B (zh) | 2012-05-11 | 2015-05-20 | 中国人民解放军军事医学科学院毒物药物研究所 | 噻唑类化合物及其用途 |
SG11201501041VA (en) | 2012-08-23 | 2015-03-30 | Virostatics Srl | Novel 4,6-disubstituted aminopyrimidine derivatives |
DK3777855T3 (da) | 2016-04-11 | 2023-01-09 | Genfit | Fremgangsmåder til behandling af fibrotiske sygdomme |
KR20200104873A (ko) | 2017-12-06 | 2020-09-04 | 린 바이오사이언스, 피티와이 엘티디. | 튜불린 억제제 |
JP7184383B2 (ja) * | 2018-02-01 | 2022-12-06 | ザ・ユニバーシティ・オブ・シドニー | 抗癌性化合物 |
JP2021526130A (ja) | 2018-06-12 | 2021-09-30 | ブイティーブイ・セラピューティクス・エルエルシー | インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用 |
EP3941900A1 (fr) | 2019-03-22 | 2022-01-26 | Deutsches Krebsforschungszentrum | Nouveaux inhibiteurs de l'histone désacétylase 10 |
EP3712127A1 (fr) | 2019-03-22 | 2020-09-23 | Deutsches Krebsforschungszentrum | Nouveaux inhibiteurs de l'histone déacétylase 10 |
EP4015506A4 (fr) * | 2019-09-25 | 2023-08-30 | Korea Institute of Radiological & Medical Sciences | Composition pour prévenir ou traiter le cancer, contenant un dérivé à base de trifluorométhylphényl pyrazole comme principe actif |
WO2021162054A1 (fr) * | 2020-02-10 | 2021-08-19 | 学校法人順天堂 | Inhibiteur de l'activité du récepteur de la ryanodine de type 2 |
CN115322208B (zh) * | 2021-05-10 | 2023-04-11 | 中国药科大学 | 2-氨基噻唑类衍生物及其制备方法和医药用途 |
AU2023239988A1 (en) * | 2022-03-22 | 2024-10-10 | Autotelic Bio Inc. | Thiazole derivative compound and uses thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL125062C (fr) * | 1960-04-20 | |||
JPH1095777A (ja) * | 1996-07-31 | 1998-04-14 | Otsuka Pharmaceut Co Ltd | チアゾール誘導体 |
TW513418B (en) * | 1996-07-31 | 2002-12-11 | Otsuka Pharma Co Ltd | Thiazole derivatives, their production and use |
US6794392B1 (en) * | 1996-09-30 | 2004-09-21 | Schering Aktiengesellschaft | Cell differentiation inducer |
YU22400A (sh) * | 1997-10-27 | 2003-08-29 | Agouron Pharmaceuticals Inc. | Supstituisana 4-amino-tiazol-2-i jedinjenja kao cdks inhibitori |
US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
JP2002518380A (ja) * | 1998-06-18 | 2002-06-25 | ブリストル−マイヤーズ スクイブ カンパニー | サイクリン依存キナーゼの炭素置換アミノチアゾール抑制剤 |
GB9823871D0 (en) * | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
CN101481359A (zh) * | 1999-04-15 | 2009-07-15 | 布里斯托尔-迈尔斯斯奎布公司 | 环状蛋白酪氨酸激酶抑制剂 |
US6114365A (en) | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
US6992081B2 (en) * | 2000-03-23 | 2006-01-31 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
SE0102440D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compound |
US6936629B2 (en) * | 2001-12-21 | 2005-08-30 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
JP4650412B2 (ja) * | 2003-01-27 | 2011-03-16 | アステラス製薬株式会社 | チアゾール誘導体およびvap−1阻害剤としてのその使用 |
-
1999
- 1999-08-12 US US09/372,832 patent/US6114365A/en not_active Expired - Lifetime
-
2000
- 2000-08-11 KR KR1020027001844A patent/KR100773709B1/ko not_active IP Right Cessation
- 2000-08-11 JP JP2001518441A patent/JP4864260B2/ja not_active Expired - Fee Related
- 2000-08-11 OA OA1200200052A patent/OA12047A/en unknown
- 2000-08-11 EP EP00962760A patent/EP1204649B1/fr not_active Expired - Lifetime
- 2000-08-11 EA EA200200247A patent/EA005375B1/ru not_active IP Right Cessation
- 2000-08-11 CN CNB008127336A patent/CN100410245C/zh not_active Expired - Fee Related
- 2000-08-11 WO PCT/IB2000/001423 patent/WO2001014353A1/fr active IP Right Grant
- 2000-08-11 AU AU74400/00A patent/AU782882B2/en not_active Ceased
- 2000-08-11 GE GE4757A patent/GEP20053475B/en unknown
- 2000-08-11 AP APAP/P/2002/002441A patent/AP1853A/en active
- 2000-08-11 DK DK00962760T patent/DK1204649T3/da active
- 2000-08-11 SI SI200030974T patent/SI1204649T1/sl unknown
- 2000-08-11 AT AT00962760T patent/ATE375987T1/de active
- 2000-08-11 PT PT00962760T patent/PT1204649E/pt unknown
- 2000-08-11 US US10/048,474 patent/US6784198B1/en not_active Expired - Fee Related
- 2000-08-11 BR BR0013281-0A patent/BR0013281A/pt not_active IP Right Cessation
- 2000-08-11 KR KR1020077014635A patent/KR100827563B1/ko not_active IP Right Cessation
- 2000-08-11 ES ES00962760T patent/ES2295056T3/es not_active Expired - Lifetime
- 2000-08-11 NZ NZ517236A patent/NZ517236A/en not_active IP Right Cessation
- 2000-08-11 DE DE60036803T patent/DE60036803T2/de not_active Expired - Lifetime
- 2000-08-11 CZ CZ20020486A patent/CZ303138B6/cs not_active IP Right Cessation
- 2000-08-11 HU HU0202492A patent/HUP0202492A3/hu unknown
- 2000-08-11 EE EEP200200064A patent/EE04939B1/xx not_active IP Right Cessation
- 2000-08-11 CA CA002381097A patent/CA2381097C/fr not_active Expired - Fee Related
- 2000-08-11 SK SK180-2002A patent/SK287373B6/sk not_active IP Right Cessation
- 2000-08-11 IL IL14792400A patent/IL147924A0/xx active IP Right Grant
- 2000-08-11 RS YUP-97/02A patent/RS50300B/sr unknown
- 2000-08-11 MX MXPA02001508A patent/MXPA02001508A/es active IP Right Grant
- 2000-11-08 UA UA2002031948A patent/UA72538C2/uk unknown
-
2002
- 2002-01-31 IL IL147924A patent/IL147924A/en not_active IP Right Cessation
- 2002-02-08 ZA ZA200201117A patent/ZA200201117B/en unknown
- 2002-02-11 IS IS6264A patent/IS2594B/is unknown
- 2002-02-11 NO NO20020683A patent/NO323576B1/no not_active IP Right Cessation
- 2002-02-12 HR HR20020127A patent/HRP20020127B1/xx not_active IP Right Cessation
- 2002-03-05 BG BG106481A patent/BG65484B1/bg unknown
- 2002-03-11 MA MA26547A patent/MA25433A1/fr unknown
-
2003
- 2003-09-11 HK HK03106484.7A patent/HK1054233B/zh not_active IP Right Cessation
-
2004
- 2004-07-29 US US10/902,326 patent/US20050004120A1/en not_active Abandoned
-
2007
- 2007-12-20 CY CY20071101629T patent/CY1107108T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0013281A (pt) | Derivados de arilmetil-carbonilamino-tiazol, processo para sua preparação e seu uso como agentes antitumorais | |
BR0013277A (pt) | Derivados de 3(5) ureido-pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais | |
BR0013143A (pt) | Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais | |
GB0102687D0 (en) | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them | |
AU2003218989A1 (en) | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | |
NO20040547L (no) | Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse. | |
BR0212841A (pt) | Derivado ativo de aminoindazole como inibidores de cinase, processo para sua preparação e composições farmacêuticas que os contém | |
MXPA02012164A (es) | Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden. | |
MXPA04000920A (es) | Derivados de aminoisoxazol activos como inhibidores de la cinasa. | |
BRPI0410563B8 (pt) | compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas | |
BRPI0418184A (pt) | derivados de pirrol[2,3-b]piridina ativos como inibidores de quinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos | |
BR0316234A (pt) | Hidroxiindóis, seu uso como inibidores de fosfodiesterase 4 e processos para a preparação dos mesmos | |
BR0008840A (pt) | Derivados de camptotecina tendo atividade antitumoral | |
BRPI0414330A (pt) | composto, processo para preparação do mesmo, métodos para produção de um efeito antibacteriano, para inibição de dna girase bacteriana, e para tratamento de uma infecção bacteriana em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
MXPA05009719A (es) | Derivados de biciclo-pirazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden. | |
EA199901031A1 (ru) | Производные бензимидазола | |
DE602004014163D1 (de) | Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken | |
BR0314195A (pt) | Derivados de piridina substituìda como agentes antitumorais |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014. |